EU/3/14/1253: Orphan designation for the prevention of graft rejection following solid organ transplantation

Ex-vivo cultured human mesenchymal stromal cells

Table of contents

Overview

On 26 March 2014, orphan designation (EU/3/14/1253) was granted by the European Commission to iCell Science AB, Sweden, for ex vivo cultured human mesenchymal stromal cells for the prevention of graft rejection following solid organ transplantation.

Key facts

Active substance
Ex-vivo cultured human mesenchymal stromal cells
Intended use
Prevention of graft rejection following solid organ transplantation
Orphan designation status
Positive
EU designation number
EU/3/14/1253
Date of designation
26/03/2014
Sponsor
iCell Science AB
Tallmov 2 A
756 45 Uppsala
Sweden
Tel. +46 183 022 98
E-mail: olle.korsgren@iCell-Science.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating